Company Overview
About ImmunoVec
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
Business Model & Competitive Advantage
ARPA-H funding is among the most selective and technically validated health research grants in the US government — the agency specifically funds technologies with potential to radically transform healthcare, not incremental improvements. ARPA-H's selection of ImmunoVec validates the non-viral in vivo CAR-T approach as a genuine national health priority with transformative potential.
Competitive Landscape 2025–2026
The platform's economic implications are significant: current CAR-T therapies require extracting patient T cells, genetically modifying them in specialized GMP facilities, expanding them in culture, and reinfusing them — a 3-4 week process costing $500,000+ per patient. ImmunoVec's in vivo approach could reduce this to an off-the-shelf infusion at 1-5% of current cost, potentially democratizing CAR-T-like immunotherapy for the 90%+ of patients who currently cannot access it.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
ImmunoVec is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare ImmunoVec with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ImmunoVec? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ImmunoVec Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ImmunoVec vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →